Bezlotoxumab

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.